A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Inclusion Criteria:

1. Aged 18 years at the time of consent.

2. Platelet count < 30,000/µL despite an adequate trial of at least one priortherapeutic attempt. Platelet counts of < 30,000/µL must be confirmed on 2 occasionsat least 5 days apart, but no more than 14 days apart.

3. Partial thromboplastin time < 1.5 x upper limit of normal (ULN), prothrombin time < 1.5 x ULN, total bilirubin < 1.5 x ULN unless due to Gilbert's syndrome, or aninternational normalized ratio < 1.5 at screening.

Exclusion Criteria:

1. CD19+ B cell count < 80 cells/µL at Screening, or < 40 cells/µL if B-cell depletingtherapy was received within 24 weeks to 2 years prior.

2. Diagnosis of paroxysmal nocturnal hemoglobinuria, Evan's Syndrome, or other bleedingdisorders affecting safety or data integrity.

3. Prior B-cell depleting therapy (e.g., rituximab) within 24 weeks before first doseor planned during the study.

4. Chronic use of anticoagulants or antiplatelet agents (e.g., aspirin, NSAIDs,thienopyridines) within 14 days before dosing through follow-up. Intermittent NSAIDuse is allowed.

5. Immunosuppressants (excluding corticosteroids) within 30 days or 5× half-life beforeScreening; alkylating agents within 180 days.

6. IVIg treatment within 90 days prior to Screening.

7. Active ITP treatment (other than steroids or TPO agonists) within 30 days or 5×half-life before first dose, unless approved by Medical Monitor.

8. Active, chronic, or latent infections including hepatitis B/C or HIV.

9. Active TB or high TB risk.